

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It was highlighted during scope consultation that certain ethnic groups (African or Caribbean and Hispanic family backgrounds) have a higher prevalence of hereditary ATTR-CM compared to the general population.

It was noted that within these groups, the disease may primarily manifest as cardiomyopathy rather than neuropathy. Responses highlighted the limited treatment options available and poorer outcomes compared to other subgroups. It was noted that any recommendation will disproportionately impact these groups compared to the wider eligible population.

It was also highlighted during scope consultation that the average age of patients likely to be suitable for this treatment is around 60-70 years of age.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

NICE considers appraisal technologies within their marketing authorisation for the whole population, and for relevant subgroups as defined in section 4.9 of the NICE health technology evaluations manual. As part of the technology appraisal, the committee will also consider the impact of recommendations on people with protected characteristics and the potential impact on health inequalities as outlined in the [NICE Principles](#).

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The final scope was updated to note that people with African or Caribbean and Hispanic family backgrounds are more likely to develop cardiomyopathy, without neuropathy.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

None.

Approved by Associate Director (name): Lorna Dunning

Date: [14/11/2024]